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durability of plaque modification.
Methods: Patients with PAD underwent primary intervention with orbital technology
followed by low pressure balloon. Lesion compliance markers, including maximum
post-orbital balloon inflation pressures, inflation times, dissection rates and bail-out
stent rates, were recorded. 12-month reintervention rates were also tracked.
Results: 46 patients (74% male, 71 yrs) with 57 fibrotic or calcified lesions. Patient
demographics: diabetes (50%), renal disease (39.1%), CAD (67%), HTN (98%),
hyperlipidemia (94%), Rutherford 3-5. Lesion locations: CFA (9%), SFA (56%),
popliteal (19%) and tibial/peroneal (16%). Average pre-treatment stenosis was 89%.
In 84% of cases, balloon inflation was utilized to achieve a mean residual stenosis of
10.5%. Mean maximum inflation pressure was 5.3 atms for a mean of 2.3 min. 1
dissection was reported. No bail-out stenting was required. 5 patients (10.9%) returned
for re-treatment of the target lesion within the 12-month follow-up period.
Conclusion: In this study, the use of orbital technology modified lesion compliance
in resistant plaques as demonstrated by low pressure and short duration post-orbital
balloon inflations. Bail-out stenting was eliminated in this challenging patient
population, and use of orbital technology resulted in durable long-term results with a
low reintervention rate.
TCT-577
TEVAR in 2011: Worldwide Experience with a Conformable Graft. Does the
Combination of Flexibility and Radial Strength Lead to Positive Outcomes in
Thoracic Pathologies?
Zvonimir Krajcer
Cardiology, Texas Heart Institute, Houston, TX
Background: The anatomies of patients treated with TEVAR are as diverse as the
pathologies that are being treated. Increased graft flexibility and conformability may
contribute to a device’s ability to adapt to these different anatomies and pathologies.
We report the worldwide experience of the Valiant thoracic stent graft (Medtronic
Vascular, Santa Rosa, Calif) in treatment across aortic pathologies.
Methods: Three major studies encompassing multiple pathologies are included in this
analysis. VALOR II: a 160 patient prospective, nonrandomized, pivotal trial conducted
in the US for the treatment of descending Thoracic Aneurysm (TAA) or degenerative
disease, The Valiant Captivia Registry: a 100 patient post market registry conducted
in Europe for the treatment of TAA or Aortic Dissection, and the VIRTUE Registry: a
100 patient prospective European registry for the treatment of acute, sub-acute, or
chronic dissection.
Results: Thirty day mortality across all studies was 3.1-4%. The incidence of stroke
at 30 days was 2.5 – 4% while spinal cord ischemia rates were less than 2%. There
were no Type 1a endoleaks reported in the VIRTUE cohort and 1.5% incidence in the
Valiant Captivia Registry group at 30 days. The incidence of Type 1 endoleak in the
VALOR II cohort was 3% at 1 year. Across all patients, there was only 1 rupture and
1 conversion which were attributed to the same patient.
Conclusion: Early results from the VALOR II Study, the Valiant Captivia Registry,
and the VIRTUE Registry demonstrate that the Valiant thoracic stent graft with its high
conformability is effective in treating a variety of thoracic aortic pathologies including
TAA and degenerative disease, as well as, acute, sub-acute, and chronic dissection.
TCT-578
Mechanical Thrombectomy in Treatment of Limb Ischemia: Interim Results of
a Prospective Multi-Center Registry
Peter Soukas6, Robert Lookstein1, Mark Garcia4, Eugene Simoni3, Ali Amin2,
Lawrence Blitz5
1Mount Sinai Medical Center, New York, NY; 2Reading Hospital, Reading, PA; 3Penn
State Hershey Heart and Vascular Institute, Hershey, PA; 4Christiana Care,
Christiana, DE; 5Chilton Memorial Hospital, Pompton Plains, NJ; 6The Miriam and
Rhode Island Hospitals, Providence, RI
Background: To report registry data in which limb ischemia patients were treated with
mechanical thrombectomy.
Methods: A two-phase ongoing prospective registry of the MEDRAD Angiojet
catheter used in the treatment of acute and chronic limb ischemia was examined.
Electronic data capture case report forms were completed by site staff collecting
patient’s history, procedural information including adjunctive treatments, outcomes
and adverse events. Phase I patients were followed to 3 months post procedure while
the ongoing phase II patients will be followed for 12 months.
Results: Currently 271 patient with acute (200/271; 74%) and chronic (71/271; 26%)
limb ischemia at 42 centers have been treated (160 male and 111 female, mean age 66;
range 21 to 96 years). All patients were treated with the Angiojet catheter, with 63%
receiving lytic delivery by the AngioJet. CDT occurred in 45%. Full patency was
achieved in 82% with a statistically significant improvement in ABIs (p<0.0001). Initial
hospitalization AEs included: bleeding requiring transfusions 10/271 (4%), bypass
surgery (11/271 (4%) and amputation 9/271 (3%). Of the 80% (218/271) with 3 month
follow ups, 7/271 (3%) reported bypass surgery and another 6/271 (6%) had an
amputation. The physical and mental QOL scores improved from baseline 37% and
11%, respectively. A 93% (124/133) limb salvage rate was reported for the acute limb
ischemia patients with baseline Rutherford classifications of IIa, IIb and III.
Conclusion: Mechanical thrombectomy combined with adjunctive treatments is an
effective and safe strategy for limb ischemia.
TCT-579
A New concept of Stent:the Multilayer Stent.First Human Study in Peripheral
Aneurysms
Michel Henry1, 2, Amira Benjelloun3, Antonios Polydorou4, Isabelle Henry5
1CABINET DE CARDIOLOGIE, Nancy, France; 2Global Research Institute,
Hyderabad, India; 3Clinique Coeur et Vaisseaux, Rabat Sale, Morocco;
4Pantaleimon General Hospital, Athens, Greece; 5Polyclinique Bois Bernard, Bois
Bernard, France
Background: Arterial aneurysms are traditionally treated surgically, but more and
more by interventional procedures using covered stents Endografts or coils with a high
technical success rate, but some problems are not solved like protection of aneurysm
rupture, endoleaks, stent thrombosis. We developed a new concept of stent, the
Multilayer stent (M.S) to treat aneurysms and try to avoid some drawbacks encountered
with endografts.
Methods: This M.S is a 3 Dimensional braided tube made of several interconnected
layers without any covering. Our earliest tests in vitro (theorical simulation,
computerized Fluid dynamics, Molecular Modelization) and in vivo tests demonstrate
that this MS reduces the velocity in the aneurismal sac up to 90% by modifying the
hemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the flow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this M.S preserves
the collateral branches allowing the possibility to cover any artery without
compromising the flow (renal, digestive arteries, supra aortic vessels …)
Results: 32 peripheral aneurysms (iliac:20, femoral:1, popliteal:4, renal:6,
mesenteric:1) were treated with the M.S, (male:25, mean age 61+/-8y) (42 stents Ø 5
to 14mm; length 40 to 100 mm) were implanted to treat these aneurysms, by femoral
approach. Technical success in all patients. No complications. All aneurysms
thrombosed with diameter reduction in some patients. 6 month to 30 month follow up
will be presented and we will discuss the time needed to achieve exclusion and the
factors influencing this exclusion. Allthe side branches remained patent.
Conclusion: A new concept of stent,is developed to treat aneurysm. It opens a new
approach to treat peripheral aneurysms avoiding most of the complications encountered
with current endovascular techniques. The results obtained seem promising. A larger
study is ongoing.
TCT-580
Clinical Evaluation of the IN.PACT Drug-eluting Balloon for Treatment of
Femoro-popliteal Arterial Disease: Twelve Month Results from a Multicenter
Italian Registry
Antonio Micari1, Angelo Cioppa5, Giuseppe Vadalà1, Fausto Castriota3, Armando
Liso2, Alfredo Marchese3, Alberto Cremonesi4, Paolo Rubino5, Giancarlo Biamino1
1GVM Care and Research, Palermo, Italy; 2GVM Care and Research, Lecce, Italy;
3GVM Care and Research, Cotignola, Italy; 4GVM Care and Research, Bari, Italy;
5Montevergine Clinic, Mercogliano(Av), Italy
Background: Conventional balloon angioplasty in Superficial femoral and popliteal
artery territories is associated with a high restenosis rates 12 months post-procedure.
Recent clinical data have suggested that use of DEBs may substantially reduce
restenosis. The impact of InPact Admiral(Medtronic Invatec, Roncadelle, Italy)DEB
use on provisional stenting and 12 month clinical outcomes in routine clinical practice
is described.
Methods: This prospective, observational registry enrolled patients with Rutherford
class 2, 3, or 4 femoropoliteal arterial disease with reference vessel diameter of 3 to 7
mm and lesion or occlusion length ≤15 cm. Endpoints included restenosis rate, target
lesion revascularization (TLR), and change in Rutherford class and ankle-brachial
index (ABI). Walking capacity and quality of life (QOL) were also assessed
Results: At 12 months follow up, 105 patients (114 lesions) were evaluable. Baseline
ABI was 0.56 ± 0.15. Baseline Rutherford classification was 26.7% for class 2, 64.8%
for class 3, and 7.6% for class 4. Most lesions were located in the middle and distal
superficial femoral artery (77.1%). The device was successfully deployed in all patients
and only 12.3% of lesions required stenting. The rate of TLR was 8.7% at 12 months.
QOL and functional status were substantially improved at all time points with 88% in
Rutherford class 0 or 1, and a mean ABI of 0.81 ± 0.4 at 12 months
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Conclusion: PTA of femoropopliteal arterial disease using a DEB resulted in consistent
clinical improvement across multiple endpoints with a very low rate of stenting.
TCT-581
Drug Eluting Balloon For Below The Knee Angioplasty Evaluation: The
DEBATE BTK Study
Francesco Liistro1, Paolo Angioli1, Simone Grotti1, Filippo Turini1, Kenneth Ducci1,
Giorgio Ventoruzzo1, Lucia Ricci2, Giovanni Falsini1, Guido Bellandi1, Leonardo
Bolognese1
1Cardiovascular, San Donato Hospital, Arezzo, Italy; 2Diabetes Unit, San Donato
Hospital, Arezzo, Italy
Background: Drug-eluting balloon showed positive results in terms of restenosis
reduction in peripheral intervention (PTA). The aim of the study is to investigate in a
randomized fashion the efficacy and safety of Paclitaxel-eluting balloon (PEB) (In.Pact
Amphirion, Invatec, Brescia, Italy) versus non drug-eluting balloon (NEB) (Amphirion
deep, Invatec, Brescia, Italy) in diabetic patients with Critical Limb Ischemia (CLI)
undergoing PTA of below-the-knee (BTK) vessels.
Methods: The study, randomized, single center, planned to enroll 150 BTK lesions,
75 lesions in PEB and 75 in NEB group, assuming the 50% absolute reduction of 1-
Year angiographic restenosis of the culprit lesion, the primary endpoint, in the PEB
group.
Results: At the moment, 84 patients with 110 lesions treated are enrolled in the study
and 1-year follow-up is available for 66 lesions in 51 patients, 30 lesions in the PEB
and 36 lesions in the conventional balloon group. No significant differences were
observed in terms of Rutherford Class, clinical and procedural characteristics among
the two groups. Mean age was 71±19 years in PEB vs 77±10 years in NEB (p=0.09),
lesion length 107±76mm vs 128±68mm respectively (p=0.2), occlusions in 82% vs
83% (p=0.9) respectively, sub-intimal recanalization in 12.1% vs 14.5% respectively
(p=0.5). At 1 year, death occurred in 8(10%) of the enrolled patients, 3 in PEB and 5
in NEB. Restenosis, assessed by angiography in 53 lesions (83% in PEB vs 77% in
NEB, p=0.2) and by Duplex Ultrasound in 10 lesions, occurred in 9(27%) PEB vs
23(63%) NEB lesions (p=0.01). Re-occlusion was present in 6(19%)PEB vs
17(44%)NEB lesions (p=0.02). No Major amputation occurred.
Conclusion: By provisional study results, PEB seems to provide better results in terms
of 1-year restenosis compared to NEB in the treatment of BTK lesions in CLI patients.
TCT-582
Endovascular Therapy of Common Femoral Arterial Disease
Philip B Dattilo1, Thomas T Tsai1, 2, Ivan P Casserly2, 1
1Cardiology, University of Colorado School of Medicine, Aurora, CO; 2Denver VA
Medical Center, Denver, CO
Background: Common femoral endarterectomy is regarded as the standard
revascularization strategy for the treatment of common femoral artery (CFA) disease.
The availability of a variety of endovascular tools has resulted in an increased number
of patients with CFA disease being treated using an endovascular strategy. We sought
to evaluate patient- and procedure-related outcomes in a contemporary series of patients
treated for CFA disease using an endovascular strategy.
Methods: All patients with obstructive CFA disease who were treated using
endovascular therapy were identified from a prospective database. Baseline patient
characteristics, anatomic details, procedural data, and clinical outcomes were assessed.
Kaplan-Meier (KM) curves for mortality, amputation-free survival, and primary and
secondary patency were generated.
Results: Between 2006 and 2011, 30 patients underwent 31 CFA procedures. The
primary etiology of CFA obstruction was atherosclerosis (58%), access-site
complication (32%), and thromboembolism (10%). Patients presented with severe
claudication (60%), critical limb ischemia (13%) or acute limb ischemia (27%). The
procedure was technically successful in 90% of cases, with all failures occurring in
patients with occlusive atherosclerosis of the CFA. Major procedural complications
occurred in 7 procedures (23%). There was no procedural mortality. The KM estimate
of survival and amputation-free survival at one-year was 96% [Standard Error
(SE)±4%] and 96% [SE±4%], respectively. In those patients who had a successful
revascularization, the one year estimate for primary and secondary patency was 88%
[SE±6%] and 92% [SE±5%], respectively. There was a non-significant trend (p=0.08)
towards worse patency in patients treated for atherosclerotic disease compared to those
with access site-related complications and thromboembolic disease.
Conclusion: Endovascular therapy for CFA obstruction is associated with a high rate
of acute technical success Primary patency in the cohort treated for access site-related
complications and thromboembolic disease is excellent. Surgical repair of
atherosclerotic disease in the CFA remains the gold standard.
TCT-583
Pathologic Features of Atherosclerotic Plaques Retrieved by Excision and
Relevant Biomarkers for the Risk Stratification of Peripheral Artery Disease
Fumiyuki Otsuka1, Lawrence A Garcia2, XiaoQing Zhao1, Qi Cheng1, Scott Brown3,
Masataka Nakano1, Renu Virmani1, Frank D Kolodgie1
1CVPath Institute, Gaithersburg, MD; 2Tufts University School of Medicine, Boston,
MA; 3Covidien/ev3, Plymouth, MN
Background: Despite the progress in endovascular treatment for peripheral artery
disease (PAD), the long-term patency rate is still suboptimal. Atherosclerotic plaque
characteristics may be predictive of future events in patients with PAD; however,
morphological plaque features and biomarkers for the risk stratification have not been
reported.
Methods: The current sub-study was conducted as part of the DEFINITIVE LE study,
where excised plaque using the SilverHawk® or TurboHawk™ Peripheral Plaque
Excision Systems (Covidien/ev3, Plymouth, MN) from 113 de novo lesions located in
the superficial femoral artery of 92 patients with claudication were evaluated.
Immunohistochemistry was performed for macrophages (CD68, CD163, CD206), T-
lymphocytes (CD3), HLA-DR, red blood cells (glycophorin A), endothelial cells (ulex),
smooth muscle cells (HHF), Toll-like receptor 4, RAGE and ENRAGE, which were
all graded semi-quantitatively. In addition, RNA and protein profiling were performed
in 20 selected cases where a total of 90 genes and 15 proteins were evaluated.
Results: Histology showed either acute or organizing thrombus in 27 patients (29%).
Patients with thrombus had significantly higher CD163, HLA-DR, and glycophorin A
expression (p=0.01, p=0.02 and p=0.01, respectively) as well as trends toward higher
CD68 and CD206 than those without thrombus. Thrombotic cases also showed
increased expression of numerous inflammatory genes such as TNF, IL-8 and
chemokines (CCL17, 26, CXCL1, 3, and 6) as well as increased levels of several
inflammatory proteins including IL-6 and IL-8. Primary patency data at 6 month was
available in 63 patients where patients with thrombus (n=17, 27%) had a significantly
lower patency rate than those without thrombus (59% [10/17] vs. 87% [40/46],
p=0.014).
Conclusion: The current preliminary analyses reveal that peripheral atherosclerotic
plaques characterized by thrombus are associated with increased expression of several
inflammatory markers and worse clinical outcome following endovascular treatment
compared to patients without thrombus.
TCT-584
Para Millennium High Risk AAA saga: A clinical dilemma but is not a major
concern for the endovascular specialist!
Niamh Hynes2, 1, Sherif Sultan1, 2
1Vascular & Endovascular Surgery, Western Vascular Institute, Galway, Ireland;
2Galway Clinic, Galway, Ireland
Background: Between 1996 and 2009, of 2868 patients referred with AAA disease,
575 have had AAA repair, performed by one specialist vascular team and two general
surgery teams.
Methods: From 1996-2009 our mean patient age has risen by an average of 0.5% per
annum from 71years in 1996 to 78years in 2009 (p=0.023). There has been a
concomitant significant rise in SVS co-morbidity score (P<0.001), Kertai-probability
index (P<0.01), SVS anatomical score (P<0.01) and the Australasian Endovascular
Aneurysm Repair Risk Assessment (ERA) Model (P<0.05) when comparing 1998 to
2009.
Results: The percentage of endovascular repairs has increased from 0 to 91% and
despite an increase in complexity and a percentage increase of Pararenal repair of <1%
in 1996 to 31% in 2009, there has been a consistent drop in peri-operative mortality
and morbidity rates. Elective operative mortality prior to the establishment of a
specialist deliberate practice volume centre and prior to the introduction of
endovascular techniques in 2002 was 15.7% per annum compared to 1.8% since 2002
(P<0.0001) Freedom from Major adverse events (MACE) has increased over the last
decade from 28% to 78% (p=0.0009, h=0.32 [95%CI=0.17 to 0.61]). Cox proportional
Hazards Ratio showed that age, gender, SVS co-morbidity score, Kertai-probability
index, SVS anatomical score and ERA Model score did not influence 5-year aneurysm
related survival or freedom from MACE.
Conclusion: Procedural innovation, minimally invasive technologies and enhanced
understanding of the management of high-risk factors have led to substantial upturn
in aneurysm survival rates and a profound recuperation of both quality of life and cost-
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